|
1
|
Burstein HJ, Prestrud AA, Seidenfeld J, et
al: American Society of Clinical Oncology: American Society of
Clinical Oncology clinical practice guideline: update on adjuvant
endocrine therapy for women with hormone receptor-positive breast
cancer. J Clin Oncol. 28:3784–3796. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Geisler J, King N, Anker G, et al: In vivo
inhibition of aromatization by exemestane, a novel irreversible
aromatase inhibitor, in postmenopausal breast cancer patients. Clin
Cancer Res. 4:2089–2093. 1998.PubMed/NCBI
|
|
3
|
Wong ST and Goodin S: Overcoming drug
resistance in patients with metastatic breast cancer.
Pharmacotherapy. 29:954–965. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moy I, Lin Z, Rademaker AW, Reierstad S,
Khan SA and Bulun SE: Expression of estrogen-related gene markers
in breast cancer tissue predicts aromatase inhibitor
responsiveness. PLoS One. 8:e775432013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Madeira M, Mattar A, Logullo AF, Soares FA
and Gebrim LH: Estrogen receptor alpha/beta ratio and estrogen
receptor beta as predictors of endocrine therapy responsiveness-a
randomized neoadjuvant trial comparison between anastrozole and
tamoxifen for the treatment of postmenopausal breast cancer. BMC
Cancer. 13:4252013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lønning PE and Eikesdal HP: Aromatase
inhibition 2013: clinical state of the art and questions that
remain to be solved. Endocr Relat Cancer. 20:R183–R201. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Normanno N, Di Maio M, De Maio E, et al:
Mechanisms of endocrine resistance and novel therapeutic strategies
in breast cancer. Endocr Relat Cancer. 12:721–747. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Macedo LF, Sabnis GJ, Goloubeva OG and
Brodie A: Combination of anastrozole with fulvestrant in the
intratumoral aromatase xenograft model. Cancer Res. 68:3516–3522.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Castellano I, Allia E, Accortanzo V, et
al: Androgen receptor expression is a significant prognostic factor
in estrogen receptor positive breast cancers. Breast Cancer Res
Treat. 124:607–617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu R, Dawood S, Holmes MD, et al: Androgen
receptor expression and breast cancer survival in postmenopausal
women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Agoff SN, Swanson PE, Linden H, Hawes SE
and Lawton TJ: Androgen receptor expression in estrogen
receptor-negative breast cancer Immunohistochemical, clinical, and
prognostic associations. Am J Clin Pathol. 120:725–731. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moinfar F, Okcu M, Tsybrovskyy O, et al:
Androgen receptors frequently are expressed in breast carcinomas:
potential relevance to new therapeutic strategies. Cancer.
98:703–711. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Niemeier LA, Dabbs DJ, Beriwal S, Striebel
JM and Bhargava R: Androgen receptor in breast cancer: expression
in estrogen receptor-positive tumors and in estrogen
receptor-negative tumors with apocrine differentiation. Mod Pathol.
23:205–212. 2010. View Article : Google Scholar
|
|
14
|
Somboonporn W and Davis SR; National
Health and Medical Research Council: Testosterone effects on the
breast: implications for testosterone therapy for women. Endocr
Rev. 25:374–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nahleh Z: Androgen receptor as a target
for the treatment of hormone receptor-negative breast cancer: an
unchartered territory. Future Oncol. 4:15–21. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morris KT, Toth-Fejel S, Schmidt J,
Fletcher WS and Pommier RF: High dehydroepiandrosterone-sulfate
predicts breast cancer progression during new aromatase inhibitor
therapy and stimulates breast cancer cell growth in tissue culture:
a renewed role for adrenalectomy. Surgery. 130:947–953. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gooren LJ: A ten-year safety study of the
oral androgen testosterone undecanoate. J Androl. 15:212–215.
1994.PubMed/NCBI
|
|
18
|
Schubert M, Minnemann T, Hübler D, et al:
Intramuscular testosterone undecanoate: pharmacokinetic aspects of
a novel testosterone formulation during long-term treatment of men
with hypogonadism. J Clin Endocrinol Metab. 89:5429–5434. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saad F, Haider A and Gooren L: Effects of
long-term treatment of hypogonadal men with testosterone
undecanoate on blood pressure, fasting glucose, HbA1c and
C-reactive protein. Endocrine Abstracts. 29:3152012.
|
|
20
|
Peters AA, Buchanan G, Ricciardelli C, et
al: Androgen receptor inhibits estrogen receptor-alpha activity and
is prognostic in breast cancer. Cancer Res. 69:6131–6140. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gonzalez LO, Corte MD, Vazquez J, et al:
Androgen receptor expresion in breast cancer: relationship with
clinicopathological characteristics of the tumors, prognosis and
expression of metalloproteases and their inhibitors. BMC Cancer.
8:1492008. View Article : Google Scholar
|
|
22
|
Labrie F, Simard J, de Launoit Y, et al:
Androgens and breast cancer. Cancer Detect Prev. 16:31–38.
1992.PubMed/NCBI
|
|
23
|
Weigelt B, Mackay A, A’hern R, et al:
Breast cancer molecular profiling with single sample predictors: a
retrospective analysis. Lancet Oncol. 11:339–349. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hugh J, Hanson J, Cheang MC, et al: Breast
cancer subtypes and response to docetaxel in node-positive breast
cancer: use of an immunohistochemical definition in the BCIRG 001
trial. J Clin Oncol. 27:1168–1176. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robinson JL, MacArthur S, Ross-Innes CS,
et al: Androgen receptor driven transcription in molecular apocrine
breast cancer is mediated by FoxA1. EMBO J. 30:3019–3027. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang Q, Li W, Zhang Y, et al: Androgen
receptor regulates a distinct transcription program in
androgen-independent prostate cancer. Cell. 138:245–256. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu R, Dawood S, Holmes MD, et al: Androgen
receptor expression and breast cancer survival in postmenopausal
women. Clin Cancer Res. 17:1867–1874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ni M, Chen Y, Lim E, et al: Targeting
androgen receptor in estrogen receptor-negative breast cancer.
Cancer Cell. 20:119–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dimitrakakis C, Jones RA, Liu A and Bondy
CA: Breast cancer incidence in postmenopausal women using
testosterone in addition to usual hormone therapy. Menopause.
11:531–535. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Santoni G and Farfariello V: TRP channels
and cancer: new targets for diagnosis and chemotherapy. Endocr
Metab Immune Disord Drug Targets. 11:54–67. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kuenen-Boumeester V, Van der Kwast TH, van
Putten W, Claassen C, Van Ooijen B and Henzen-Logmans SC:
Immunohistochemical determination of androgen receptors in relation
to oestrogen and progesterone receptors in female breast cancer.
Int J Cancer. 52:581–584. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hickey TE, Robinson JL, Carroll JS and
Tilley WD: Minireview: The androgen receptor in breast tissues:
growth inhibitor, tumorsuppressor, oncogene? Mol Endocrinol.
26:1252–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tokunaga E, Hisamatsu Y, Taketani K, et
al: Differential impact of the expression of the androgen receptor
by age in estrogen receptor-positive breast cancer. Cancer Med.
2:763–773. 2013. View
Article : Google Scholar
|
|
34
|
Doane AS, Danso M, Lal P, Donaton M, Zhang
L, Hudis C and Gerald WL: An estrogen receptor-negative breast
cancer subset characterized by a hormonally regulated
transcriptional program and response to androgen. Oncogene.
25:3994–4008. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu Q, Niu Y, Liu N, et al: Expression of
androgen receptor in breast cancer and its significance as a
prognostic factor. Ann Oncol. 22:1288–1294. 2011. View Article : Google Scholar
|
|
36
|
Campagnoli C, Pasanisi P, Castellano I,
Abba C, Brucato T and Berrino F: Postmenopausal breast cancer,
androgens, and aromatase inhibitors. Breast Cancer Res Treat.
139:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu CQ, Wu SZ, Wang ZD, Lai WY and Sun F:
Effect of testosterone on expression of androgen receptor in human
monocytic cell line THP-1. Di Yi Jun Yi Da Xue Xue Bao. 24:389–391.
2004.In Chinese. PubMed/NCBI
|
